NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SWTX

SpringWorks Therapeutics Inc

Apr 17 • 03:02PM ET

37.67

Dollar change -0.07
Percentage change -0.19	%

Healthcare • Biotechnology • USA • NASD

Peers: ARGX FGEN NBIX BPMC SRPT RARE PRTA SAGE VRTX ACAD

| Held by: VTI VB IWM XBI VXF VBK IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.48	Insider Own	6.15%	Shs Outstand	74.40M	Perf Week	9.40%
Market Cap	2.82B	Forward P/E	-	EPS next Y	-0.42	Insider Trans	-10.20%	Shs Float	70.37M	Perf Month	-25.60%
Income	-258.13M	PEG	-	EPS next Q	-0.76	Inst Own	105.87%	Short Float	11.77%	Perf Quarter	5.84%
Sales	191.59M	P/S	14.74	EPS this Y	35.11%	Inst Trans	1.10%	Short Ratio	3.29	Perf Half Y	23.50%
Book/sh	6.47	P/B	5.83	EPS next Y	81.25%	ROA	-39.32%	Short Interest	8.28M	Perf Year	-13.21%
Cash/sh	4.11	P/C	9.17	EPS next 5Y	-	ROE	-46.62%	52W Range	28.21 - 62.00	Perf YTD	4.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.25%	ROI	-52.97%	52W High	-39.25%	Beta	0.84
Dividend TTM	-	Quick Ratio	3.70	Sales past 5Y	663.47%	Gross Margin	91.64%	52W Low	33.52%	ATR (14)	2.94
Dividend Ex-Date	-	Current Ratio	3.81	EPS Y/Y TTM	30.06%	Oper. Margin	-145.17%	RSI (14)	38.70	Volatility	6.57% 6.87%
Employees	368	Debt/Eq	0.02	Sales Y/Y TTM	3417.33%	Profit Margin	-134.73%	Recom	1.12	Target Price	72.50
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	19.06%	Payout	-	Rel Volume	0.43	Prev Close	37.74
Sales Surprise	7.67%	EPS Surprise	-47.08%	Sales Q/Q	1029.96%	Earnings	Feb 20 BMO	Avg Volume	2.52M	Price	37.67
SMA20	-9.55%	SMA50	-21.88%	SMA200	-4.06%	Trades		Volume	925,882	Change	-0.19%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-24	Initiated	Evercore ISI	Outperform	$60
Feb-05-24	Initiated	Guggenheim	Buy	$75
Dec-01-22	Initiated	BofA Securities	Buy	$45
Jan-19-21	Reiterated	H.C. Wainwright	Buy	$87 → $101
Oct-29-20	Reiterated	H.C. Wainwright	Buy	$58 → $73
May-05-20	Initiated	Barclays	Overweight	$48
Mar-19-20	Upgrade	H.C. Wainwright	Neutral → Buy	$40 → $60
Mar-04-20	Downgrade	H.C. Wainwright	Buy → Neutral	$40
Jan-21-20	Reiterated	H.C. Wainwright	Buy	$34 → $40
Dec-04-19	Initiated	H.C. Wainwright	Buy
Oct-08-19	Initiated	Wedbush	Outperform	$33
Oct-08-19	Initiated	JP Morgan	Overweight	$32
Oct-08-19	Initiated	Goldman	Buy	$37
Oct-08-19	Initiated	Cowen	Outperform

Show Previous Ratings

Mar-01-25 02:41PM	Is SpringWorks Therapeutics, Inc. (SWTX) The Best Immunology Stock To Buy Now? (Insider Monkey)
Feb-23-25 03:17PM	Why SpringWorks Therapeutics, Inc. (SWTX) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-20-25 09:01AM	SpringWorks Therapeutics Inc (SWTX) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com) +7.54%
06:30AM	SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Feb-19-25 08:00AM	SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over (PR Newswire)
05:38AM	Loading…
Feb-18-25 05:38AM	SpringWorks Therapeutics selects Onco360 as pharmacy partner for Gomekli (Pharmaceutical Business Review)
Feb-13-25 11:05AM	Wedbush ups SpringWorks target to $81, expects Merck KGaA official offer soon (TipRanks)
11:00AM	SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg (TipRanks)
10:50AM	SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25 (TipRanks)
Feb-11-25 08:20PM	UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN (GlobeNewswire) +7.53%
05:27PM	SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN (GlobeNewswire)
02:07AM	Germanys Merck in Talks to Buy SpringWorks Therapeutics (The Wall Street Journal)
Jan-30-25 07:00AM	SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025 (GlobeNewswire)
Jan-13-25 02:47PM	SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 (Investor's Business Daily) -13.93%
06:30AM	SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:40AM	Loading…
Jan-09-25 08:40AM	SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim (TipRanks)
Jan-08-25 02:54PM	SpringWorks Therapeutics Stock Gets A RS Rating Lift (Investor's Business Daily)
07:26AM	SpringWorks Therapeutics price target lowered to $55 from $58 at BofA (TipRanks)
Jan-03-25 06:30AM	SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.85%
Nov-26-24 07:00AM	SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire) +5.30%
Nov-13-24 02:10AM	SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-12-24 09:25AM	SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
06:43AM	SpringWorks Therapeutics mirdametinib shows efficacy in neurofibromatosis study (TipRanks)
06:30AM	SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-11-24 07:08AM	Earnings To Watch: SpringWorks Therapeutics Inc (SWTX) Reports Q3 2024 Result (GuruFocus.com)
07:00AM	SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
06:30AM	SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology (GlobeNewswire)
Nov-07-24 06:30AM	SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting (GlobeNewswire)
Nov-05-24 07:00AM	SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
07:00AM	Loading…
Oct-22-24 07:00AM	SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-09-24 05:12PM	SpringWorks Therapeutics Inc (SWTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Sep-04-24 07:00PM	SpringWorks Therapeutics Inc (SWTX) CEO Saqib Islam Sells 49,000 Shares (GuruFocus.com)
Aug-28-24 06:30AM	FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN (GlobeNewswire)
Aug-07-24 06:30AM	SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-29-24 06:30AM	SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors (GlobeNewswire)
Jul-23-24 07:00AM	SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 (GlobeNewswire)
Jul-12-24 11:27AM	SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why (Zacks)
Jul-02-24 12:12PM	SpringWorks (SWTX) Completes NDA Submission for Mirdametinib (Zacks)
Jul-01-24 06:30AM	SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN (GlobeNewswire)
Jun-06-24 02:34AM	Insider Sale: Director Julie Hambleton Sells Shares of SpringWorks Therapeutics Inc (SWTX) (GuruFocus.com)
02:34AM	Insider Sale: COO Badreddin Edris Sells 20,000 Shares of SpringWorks Therapeutics Inc (SWTX) (GuruFocus.com)
02:34AM	Insider Sale: CEO Saqib Islam Sells 49,000 Shares of SpringWorks Therapeutics Inc (SWTX) (GuruFocus.com)
Jun-05-24 07:00AM	SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-23-24 05:13PM	SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-08-24 07:00AM	SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference (GlobeNewswire) -7.63%
May-03-24 03:18AM	SpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 10:53AM	SWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024 (InvestorPlace) -7.45%
07:45AM	SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Apr-24-24 01:31PM	SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-18-24 07:00AM	SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 (GlobeNewswire)
Mar-04-24 06:30AM	SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN (GlobeNewswire)
Feb-29-24 08:30AM	SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors (GlobeNewswire)
Feb-27-24 07:12AM	SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com) +7.41%
06:30AM	SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Feb-22-24 07:00AM	SpringWorks Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-07-24 02:42AM	SpringWorks Therapeutics Inc Insider Sells Company Shares (GuruFocus.com) -8.80%
Feb-05-24 11:26PM	SpringWorks Therapeutics Inc Chief People Officer Daniel Pichl Sells 26,181 Shares (GuruFocus.com)
Jan-31-24 07:00AM	SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 06:30AM	SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +9.40%
Dec-21-23 07:00AM	SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-23 04:05PM	SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-05-23 12:32AM	SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) -8.59%
Dec-04-23 04:13PM	SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-29-23 07:00AM	SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +8.84%
Nov-28-23 04:41PM	SpringWorks Therapeutics Shares Skyrocket on FDA Approval of Desmoid Tumor Drug (Investopedia) +18.68%
04:03PM	SpringWorks Catapults 19% On A 'Watershed Moment' In Cancer Treatment (Investor's Business Daily)
Nov-27-23 06:04PM	SpringWorks Therapeutics Announces FDA Approval of OGSIVEO (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors (GlobeNewswire)
Nov-16-23 06:30AM	SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN (GlobeNewswire) -7.34%
Nov-02-23 07:54AM	SpringWorks Therapeutics Inc (SWTX) Reports Q3 2023 Financial Results (GuruFocus.com) +5.60%
06:30AM	SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-01-23 06:30AM	SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting (GlobeNewswire)
Sep-11-23 06:30AM	SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer (GlobeNewswire)
Aug-02-23 06:30AM	SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) -6.87%
Jun-28-23 08:29PM	Goldman Sachs Says Attractive Valuations Make Small-Cap Stocks Appealing; Here Are 2 Strong Buy Names With Solid Upside Potential (TipRanks)
Jun-07-23 07:00AM	SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-05-23 06:30AM	SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA (GlobeNewswire)
May-30-23 06:30AM	SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors (GlobeNewswire)
May-25-23 05:05PM	SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting (GlobeNewswire) -7.13% -7.51%
May-24-23 07:00AM	SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit (GlobeNewswire)
May-11-23 12:14PM	SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress (GlobeNewswire) +6.71%
May-03-23 06:30AM	SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
May-02-23 07:00AM	SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
Apr-17-23 02:32PM	SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
02:30PM	MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-08-23 05:05PM	SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors (GlobeNewswire)
Mar-01-23 07:00AM	SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-28-23 06:30AM	SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-27-23 06:30AM	SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors (GlobeNewswire)
Jan-09-23 06:30AM	SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-23 07:00AM	SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-22 06:30AM	SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors (GlobeNewswire)
Nov-22-22 07:00AM	SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference (GlobeNewswire)
Nov-03-22 06:30AM	SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-01-22 11:07AM	Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma (PR Newswire)
Sep-29-22 06:30AM	SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors (GlobeNewswire)
Sep-10-22 10:30AM	SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 (GlobeNewswire)
Sep-07-22 09:56AM	SpringWorks Therapeutics Announces $225 Million Private Placement Financing (GlobeNewswire) +7.15%
09:55AM	SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma (GlobeNewswire)

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Edris Badreddin	Chief Operating Officer	Mar 03 '25	Sale	54.23	20,000	1,084,592	169,712	Mar 05 06:33 PM
Islam Saqib	Chief Executive Officer	Mar 03 '25	Sale	54.24	49,000	2,657,656	954,869	Mar 05 06:32 PM
Islam Saqib	Chief Executive Officer	Feb 20 '25	Sale	60.30	29,328	1,768,401	1,034,625	Feb 24 06:58 PM
Ashar Bhavesh	Chief Commercial Officer	Feb 20 '25	Sale	61.19	1,016	62,168	62,053	Feb 24 06:58 PM
LYNCH DANIEL	Director	Feb 20 '25	Sale	60.22	47,600	2,866,534	82,944	Feb 24 06:57 PM
Bhavesh Ashar	Officer	Feb 20 '25	Proposed Sale	61.38	16,090	987,604		Feb 20 04:18 PM
Islam Saqib	Chief Executive Officer	Feb 14 '25	Sale	59.92	10,672	639,490	1,063,953	Feb 19 04:50 PM
LYNCH DANIEL	Director	Feb 14 '25	Sale	60.00	400	24,000	130,544	Feb 19 04:49 PM
DANIEL LYNCH	Director	Feb 14 '25	Proposed Sale	58.59	48,000	2,812,320		Feb 14 04:21 PM
Pichl Daniel	Chief People Officer	Feb 10 '25	Option Exercise	27.64	29,750	822,290	80,512	Feb 12 08:01 PM
Pichl Daniel	Chief People Officer	Feb 10 '25	Sale	54.36	29,750	1,617,329	50,762	Feb 12 08:01 PM
LYNCH DANIEL	Director	Feb 10 '25	Sale	54.46	175,000	9,530,351	130,944	Feb 12 07:59 PM
Islam Saqib	Chief Executive Officer	Feb 10 '25	Sale	53.30	48,000	2,558,237	1,002,502	Feb 12 07:58 PM
Hambleton Julie	Director	Feb 10 '25	Option Exercise	32.27	13,774	444,487	17,869	Feb 12 07:57 PM
Hambleton Julie	Director	Feb 10 '25	Sale	53.01	13,774	730,207	4,095	Feb 12 07:57 PM
Edris Badreddin	Chief Operating Officer	Feb 10 '25	Sale	53.13	30,000	1,593,795	189,712	Feb 12 07:55 PM
Saqib Islam	Officer	Feb 10 '25	Proposed Sale	53.30	137,000	7,301,552		Feb 10 04:38 PM
DANIEL LYNCH	Director	Feb 10 '25	Proposed Sale	40.28	175,000	7,049,000		Feb 10 04:29 PM
Daniel Pichl	Officer	Feb 10 '25	Proposed Sale	54.36	29,750	1,617,329		Feb 10 04:13 PM
Julie Hambleton	Board Member	Feb 10 '25	Proposed Sale	53.01	13,774	730,207		Feb 10 04:09 PM
Badreddin Edris	Officer	Feb 10 '25	Proposed Sale	41.00	50,000	2,050,000		Feb 10 04:08 PM
Edris Badreddin	Chief Operating Officer	Dec 03 '24	Sale	41.97	20,000	839,336	209,600	Dec 05 06:14 PM
Islam Saqib	Chief Executive Officer	Dec 02 '24	Sale	41.37	49,000	2,027,357	1,014,368	Dec 04 04:23 PM
Islam Saqib	Chief Executive Officer	Sep 03 '24	Sale	40.57	49,000	1,988,033	1,063,368	Sep 04 04:05 PM
Edris Badreddin	Chief Operating Officer	Sep 03 '24	Sale	40.65	20,000	812,954	229,600	Sep 04 04:05 PM
Badreddin Edris	Officer	Sep 03 '24	Proposed Sale	41.78	50,000	2,089,000		Sep 03 04:09 PM
Saqib Islam	Officer	Sep 03 '24	Proposed Sale	41.58	146,000	6,070,680		Sep 03 04:07 PM
Islam Saqib	Chief Executive Officer	Jun 03 '24	Sale	39.90	49,000	1,955,113	1,112,368	Jun 05 04:08 PM
Hambleton Julie	Director	Jun 03 '24	Sale	40.03	4,648	186,048	4,095	Jun 05 04:08 PM
Edris Badreddin	Chief Operating Officer	Jun 03 '24	Sale	40.07	20,000	801,372	249,600	Jun 05 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SWTX

SpringWorks Therapeutics Inc

Upgrade your FINVIZ experience